<DOC>
	<DOCNO>NCT01015729</DOCNO>
	<brief_summary>The purpose study investigate whether fix dose combination ( FDC ) capsule esomeprazole 20 mg acetylsalicylic acid ( ASA ) 81 mg equivalent therapeutic efficacy compare 2 free combination ASA tablet 81 mg plus esomeprazole 20 mg patient risk gastrointestinal event use low dose ASA cardiovascular protection .</brief_summary>
	<brief_title>Study Comparing Esomeprazole ASA Combined Together One Capsule Versus These Medications Taken Separately</brief_title>
	<detailed_description />
	<mesh_term>Peptic Ulcer</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<criteria>Nonsmoking male female subject , age 18 year older document history uncomplicated peptic ulcer ( ) , age 65 year old Body Mass Index ( BMI = weight/height2 ) great equal 18.5 kg/m2 less equal 35.0 kg/m2 Known history hypersensitivity esomeprazole ( e.g . Nexium® ) relate drug omeprazole ( e.g . Losec® , Prilosec® ) , lansoprazole ( e.g . Prevacid® , HpPAC® ) , pantoprazole ( e.g . Pantoloc® , PANTO® IV ) , rabeprazole ( e.g . Pariet™ ) , know hypersensitivity ASA ( e.g . Aspirin® ) and/or relate drug ibuprofen ( e.g . Motrin® , Advil® ) , indomethacin ( e.g . Indocin® ) , diclofenac ( e.g . Voltaren® ) , naproxen ( e.g . Aleve® , Naprosyn® ) , ketoprofen ( e.g . Rhovail® ) . Significant history pulmonary , endocrine , musculoskeletal , neurological , hematological , liver kidney disease , gastrointestinal disease ( exception uncomplicated peptic ulcer ) , unless deem NCS Principal Investigator Subinvestigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>ASA</keyword>
	<keyword>Esomeprazole</keyword>
	<keyword>peptic ulcer disease</keyword>
	<keyword>pH measurement</keyword>
</DOC>